← All trials
NCT07063693
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2025
- Primary completion
- Jul 31, 2028
- Completion date
- Dec 31, 2028
- First posted
- Jul 14, 2025
- Last posted
- Sep 24, 2025
- Enrollment
- 33
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Dartmouth UniversityLead sponsor
- Dartmouth UniversitySponsor investigator
- Dartmouth UniversityCollaborator
- Dartmouth UniversityOfficial
- National Cancer Institute (NCI)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.